Trial · NCT03066830
Adverse events162
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 162
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 11 | 253 | |
| other | Diarrhoea | Gastrointestinal disorders | Sotagliflozin 400 mg | 22 | 254 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Placebo | 48 | 253 | |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Sotagliflozin 400 mg | 14 | 254 | |
| other | Nasopharyngitis | Infections and infestations | Placebo | 23 | 253 | |
| other | Nasopharyngitis | Infections and infestations | Sotagliflozin 400 mg | 21 | 254 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 19 | 253 | |
| other | Upper respiratory tract infection | Infections and infestations | Sotagliflozin 400 mg | 9 | 254 | |
| other | Urinary tract infection | Infections and infestations | Placebo | 8 | 253 | |
| other | Urinary tract infection | Infections and infestations | Sotagliflozin 400 mg | 19 | 254 | |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 2 | 253 | |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 254 | |
| serious | Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 253 | |
| serious | Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 254 | |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 253 | |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 254 | |
| serious | Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 253 | |
| serious | Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 254 | |
| serious | Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 253 | |
| serious | Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 254 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03066830/events